Rishi Sunak yesterday committed to rolling out weight-loss jabs to assist fix the nation’s health problems.
His announcement follows landmark research showing that semaglutide can slash the possibilities of dying from heart attack and stroke.
The breakthrough, presented this week on the European Congress of Obesity in Venice, has been hailed as probably the most significant development in heart disease since statins within the Nineties.
A spokesman for No 10 said the Prime Minister welcomed the findings of the University College London research. He added: ‘This latest study is welcome because we all know the potential for obesity medicines to assist more people each drop a few pounds but, as this study suggests, also cut wider health conditions.
‘That’s why we’re committed to the protected introduction of recent approved weight-loss drugs into the NHS, in addition to improving access to existing drugs for many who meet the eligibility criteria.’
Rishi Sunak yesterday committed to rolling out weight-loss jabs to assist fix the nation’s health problems
His announcement follows landmark research showing that semaglutide can slash the possibilities of dying from heart attack and stroke (stock image)
Experts said it might be dished out to patients in the identical way statins or blood pressure pills are given to tens of millions now. In a serious speech earlier this week, Mr Sunak acknowledged the large role the drug – which is approved as Ozempic and Wegovy – could have.
He said: ‘You can see the chance in healthcare, giving people longer, healthier lives. In Denmark, NovoNordisk created the Ozempic drug which will not be only helping to tackle chronic disease globally, but singlehandedly grew Denmark’s economy last yr.’
The research, which involved greater than 17,000 obese and obese patients, found that taking a once-weekly jab cut the possibilities of dying or suffering further attacks by a fifth.
Speaking on the conference, lead researcher Professor John Deanfield said semaglutide ‘targets the underlying biology of chronic diseases’, proving it could be used for other illnesses.
Experts said it might be dished out to patients in the identical way statins or blood pressure pills are given to tens of millions now. In a serious speech earlier this week, Mr Sunak acknowledged the large role the drug – which is approved as Ozempic and Wegovy – could have.
He said: ‘You can see the chance in healthcare, giving people longer, healthier lives.
In Denmark, NovoNordisk created the Ozempic drug which will not be only helping to tackle chronic disease globally, but singlehandedly grew Denmark’s economy last yr.’
Semaglutide is the primary in a brand new generation of medication that suppress appetite by mimicking the hormone GLP-1. It was initially used for diabetes under the brand name Ozempic before being repurposed because the weight-loss drug Wegovy.
Experts consider the advantages of the drug extend beyond weight-loss, with trials ongoing into illnesses including Parkinson’s and kidney disease.